{"disease":{"id":"superficial-basal-cell-carcinoma","name":"Superficial basal cell carcinoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"chembl-chembl185","indication_name":"Superficial Basal Cell Carcinomas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLUOROURACIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"5-fu","indication_name":"Superficial basal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"5-fu","company_name":"Spectrum Pharms","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"fluorouracil","indication_name":"Superficial basal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carac","generic_name":"fluorouracil","company_name":"Extrovis","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"imiquimod","indication_name":"Superficial basal cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldara","generic_name":"IMIQUIMOD","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"7,8-dihydro-8-oxoguanine triphosphatase","drug_class":"imiquimod","quality_score":75,"revenue":null,"mechanism":"Aldara works by activating the immune system to recognize and attack abnormal cells."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07384078","title":"High Intensity Focused Ultrasound vs. Cryotherapy in the Treatment of Basal Cell Carcinomas and Bowen's Disease in Adults","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":294,"lead_sponsor_name":"Jussi Salonen","has_results":false},{"nct_id":"NCT05628714","title":"A Patient Decision Aid for Patients With Superficial Basal Cell Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT04744935","title":"Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Christopher Zachary","has_results":false},{"nct_id":"NCT04470726","title":"Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"AiViva BioPharma, Inc.","has_results":false},{"nct_id":"NCT04552990","title":"Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05713760","title":"Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Austin Institute for Clinical Research","has_results":false}],"total":6},"guidelines":[{"drug_id":"fluorouracil","guideline_body":"FDA label","recommendation":"In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}